Ozempic Wars | The Next Injection

0:00-36:48

Novo Nordisk can't keep up with demand for Ozempic and Wegovy, giving competitor Eli Lilly the edge in the GLP-1 market. And off-brand competitors continue to hammer the company's market position. Layoffs and board resignations signal that Novo Nordisk has entered a downward spiral. But with new leaders, acquisitions and deals, can they force a comeback? See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Publisher

Business Wars

Published

November 26, 2025

Duration

37 min

Format

Podcast

Category

Issues · Entrepreneurship

Source

RSS feed

BW

Business Wars

@businesswars

#ozempicwars #injection

The Nile